Skip to Main Content

A trio of senators — including presidential candidates Elizabeth Warren and Bernie Sanders — wants more scrutiny of for-profit institutional review boards, which decide whether to green-light clinical trials.

In letters sent this week to the U.S.’s two largest commercial IRBs — WCG Clinical, better known as WIRB-Copernicus Group, and Advarra — the senators wrote that such boards “can be inherently vulnerable to conflicts of interest that could inhibit their ability to protect research subjects.” 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!